Martin K. Bayliss

ADME/PK as part of a rational approach to drug discovery

Peter Eddershaw, Alan Beresford, Martin K. Bayliss · Drug Discovery Today · 2000 · 242 citations

Pharmacy, Pharmacokinetics, Pharmacology +11

Microsomal prediction of <i>in vivo</i> clearance of CYP2C9 substrates in humans

David Carlile, Nancy Hakooz, Martin K. Bayliss et al. · British Journal of Clinical Pharmacology · 1999 · 117 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Parallel ultra-high flow rate liquid chromatography with mass spectrometric detection using a multiplex electrospray source for direct, sensitive determination of pharmaceuticals in plasma at extremely high throughput

Martin K. Bayliss, David Little, David N. Mallett et al. · Rapid Communications in Mass Spectrometry · 2000 · 83 citations

Pharmacy, Chemistry, Pharmaceutical Analysis +13

A Comparison of the Expression and Metabolizing Activities of Phase I and II Enzymes in Freshly Isolated Human Lung Parenchymal Cells and Cryopreserved Human Hepatocytes

Graham Somers, N. Lindsay, B. M. Lowdon et al. · Drug Metabolism and Disposition · 2007 · 79 citations

Medicine, Biochemistry, Pharmacology +12

Utility of hepatocytes to model species differences in the metabolism of loxtidine and to predict pharmacokinetic parameters in rat, dog and man

Martin K. Bayliss · Xenobiotica · 1999 · 70 citations

Pharmacy, Pharmacokinetics, Pharmacology +17